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Abstract  
 
Mutations of the von Hippel-Lindau gene (VHL) are frequent in clear cell renal cell 
carcinomas (ccRCC). Nonsense and frameshift mutations abrogate the function of the VHL 
protein (pVHL), whereas missense mutations can have different effects. To identify those 
missense mutations with functional consequences, we sequenced VHL in 256 sporadic 
ccRCC and identified 187 different VHL mutations of which 65 were missense mutations. 
Location and destabilizing effects of VHL missense mutations were determined in silico. The 
majority of the thermodynamically destabilizing missense mutations were located in exon 1 
in the core of pVHL, while protein surface mutations in exon 3 affected the interaction 
domains of elongin B and C. Their impact on pVHL's functionality was further investigated in 
vitro by stably re-introducing VHL missense mutations into a VHL null cell line and by 
monitoring the GFP signals after the transfection of a HIFα-GFP expression vector. 
pVHL's functionality ranged from no effect to complete HIF stabilization. Interestingly, 
Asn78Ser, Asp121Tyr, and Val130Phe selectively influenced HIF1α and HIF2α degradation. 
In sum, we obtained three different groups of missense mutations: one with severe 
destabilization of pVHL, a second without destabilizing effects on pVHL but relevance for the 
interaction with HIFα, elongin B, and elongin C, and a third with pVHL functions comparable 
to wild-type. We therefore conclude that the specific impact of missense mutations may help 
to distinguish between driver and passenger mutations and may explain responses of 
ccRCC patients to HIF targeted therapies. 
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Introduction 
 
Renal cell carcinoma (RCC) is the most frequent malignant tumor arising from the kidney 
with approximately 210,000 new cases diagnosed per year worldwide (1). About 80% of the 
RCC belong to the clear cell subtype (ccRCC) which is commonly characterized by loss of 
one short arm of chromosome 3 and mutation of the von Hippel-Lindau (VHL) tumor 
suppressor gene on the second short arm of chromosome 3 at position 3p25. The high rate 
of VHL mutations suggests that the inactivation of the multiadaptor protein pVHL plays a 
critical part in ccRCC initiation (2).  
The best investigated function of pVHL is its role as a substrate recognition component of an 
E3 ubiquitin protein ligase complex (3). Under normoxic conditions pVHL binds the 
hydroxylated HIFα subunits which leads to their ubiquitination and degradation (4). Under 
hypoxic conditions or absence of pVHL the stabilization of HIFα leads to the formation of a 
heterodimer with HIF1β which initiates enhanced transcription of HIF target genes. Both 
HIF1α and HIF2α show common but also distinct transcription patterns. HIF1α preferably 
drives the expression of genes important for apoptotic and glycolytic pathways, whereas 
HIF2α activates genes involved in cell proliferation and angiogenesis (5-7). Based on these 
results it was suggested that HIF2α is more oncogenic than HIF1α. This finding was 
supported by the observation that silencing of HIF2α in a human VHL-negative RCC cell line 
was sufficient to prevent tumor formation in mice and that HIF2α promotes c-myc activity (8-
11). However, recent evidence suggests that HIF1α is responsible for genomic instability 
which may favor the accumulation of additional genetic hits leading to carcinogenesis (12).  
Over 800 VHL mutations were identified in both hereditary and sporadic ccRCC (13). More 
than 50% of these mutations are frameshift and nonsense mutations which are highly likely 
to cause loss of pVHL function (14, 15). Due to of the large number of missense mutations 
distributed over the three exons of VHL, the consequences of such alterations on pVHL’s 
integrity and HIFα stabilization are difficult to predict.  
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Several studies have been performed to classify VHL mutations identified in the hereditary 
VHL syndrome (reviewed in (16)). Nonsense and frameshift mutations generating VHL-null 
alleles are associated with ccRCC (Type 1 VHL disease), whereas Type 2 VHL disease is 
mainly characterized by missense mutations. This type is further subdivided into type 2A 
(with low risk of ccRCC), type 2B (with high risk of ccRCC) and type 2C which predisposes 
for pheochromocytoma. Missense mutations affecting pVHL’s surface result in a higher risk 
for developing pheochromocytoma compared to substitutions altering the protein core (17). 
Forman and co-workers used bioinformatic tools to determine the thermodynamic change of 
missense mutations and linked destabilizing mutations in the interface of HIFα and elongin B 
to a prevalence of ccRCC, while mutations interfering with the elongin C interface resulted in 
increased risk of pheochromocytoma (18).  
Controversial data exist about the prognostic and predictive value of the VHL mutation type 
in sporadic ccRCC. Some groups found a correlation between “loss-of-function” mutations 
(nonsense, frameshift) and a worse prognosis for patients or higher HIF target-directed 
response rates, whereas other groups were not able to confirm these results (for review see 
(16)). A large study at the Dana-Faber Cancer Institute revealed an increased response in 
ccRCC patients with “loss-of-function” mutations (nonsense, frameshift, in frame) treated 
with antiangiogenic therapies (sunitinib, sorefanib, axitinib, or bevacizumab), blocking some 
of the downstream effects of pVHL (19). In contrast to nonsense, frameshift, and in frame 
mutations, the impact of missense mutations on the function of pVHL seems to be highly 
diversified ranging from imperceptable to complete functional loss (20-22).  
The goal of our study was to functionally characterize missense mutations in sporadic 
ccRCC on pVHL and HIF using a combination of in silico and in vitro assays. 
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Materials and Methods 
 
Tissue specimens  
Two hundred and fifty-six formalin fixed, paraffin embedded (FFPE) ccRCC samples were 
histologically reviewed by one pathologist (H.M.). This study was approved by the local 
commission of ethics (ref. number StV 38-2005). Survival time was obtained for 123 patients 
(48%). The mean age of patients was 64 (31-88) and the mean follow-up of patients was 47 
months (0-139). Tumors were graded according to tumor stage (pT) and the Fuhrman 
grading system and histologically classified according to the World Health Organization 
classification (23). The histological data are listed in supplementary Table S2.  
 
VHL mutation analysis   
For DNA extraction three tissue cylinders (diameter 0.6 mm) were punched from each 
paraffin block. DNA was extracted according to the QIAGEN EZ1 DNA Tissue protocol for 
automated purification of DNA from tissue (Qiagen, Hilden, Germany). PCR was performed 
as previously described (24) with slight modifications. Only one PCR step with 40 cycles was 
carried out using unlabelled primers. As mutations are rare in the 5’ region of exon 1 the first 
162 coding basepairs of VHL were excluded from sequence analysis (25). DNA sequencing 
was performed using the BigDye® Terminator v1.1 Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA, USA). The obtained sequences were compared with the NCBI 
sequence AF010238 using NCBIs Blast 2 Sequences. VHL point mutations were validated 
by a second separate PCR and sequencing analysis.  
 
In silico analysis of VHL mutants 
Two crystal structures of pVHL in complex with elongin B, elongin C, and the HIF peptides 
are available (26, 27) and stored in the Piccolo database of protein interaction (PDB codes 
1lm8 and 1lqb (28)). As input for in silico analyses pVHL was separated from the VCB 
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complex stored in the piccolo database 1LM8.pdb. Swiss PDB viewer ‘Deep View v.4.0’ 
(http://spdbv.vital-it.ch/) was used to locate the missense mutation either to the surface of 
pVHL or to its core. A threshold for amino acids (aa) with a solvent accessibility of more than 
9% was defined as ‘surface’ (29). To predict the association of disease due to missense 
mutations, the program Site Directed Mutator (SDM) was used which was developed by the 
Crystallography and Bioinformatic group from the University of Cambridge (30, 31). SDM 
calculates the thermodynamic change (ddG) of the protein after one missense mutation (32, 
33). A |ddG| > 2 is set by the algorithm as a cut-off for a disease-associated mutation. The 
program Crescendo, which predicts the most essential regions and aa for protein-protein 
interactions due to conserved regions was used to analyze the impact of missense 
mutations on protein-protein interactions (34). 
 
Cell culture 
Human RCC4 cells negative for pVHL, hTERT RPE-1 positive for pVHL19 (kindly provided 
by Wilhelm Krek, Institute of Cell Biology, ETH Zurich, Switzerland) and mouse embryonic 
fibroblasts (MEFs) negative for pVHL and p53 (kindly provided by Ian Frew, Institute of 
Physiology, University of Zurich, Switzerland) were grown in DMEM supplemented with 10% 
FCS in a humified incubator with 5% CO2 at 37°C. RCC4 and hTERT RPE-1 cell lines were 
authenticed by STR profiling at the dates 15.3.2011 and 26.4.2011, respectively, which was 
performed by Identicell (Dept. of Molecular Medicine, Aarhus University Hospital Skejby, 
Aarhus, Denmark). The MEF VHL null / p53 null cell line was generated after SV40 infection 
for transformation, adenoviral cre-recombinase infection for pVHL and p53 knock-out, and 
single cell cloning. MEFs were not authenticed. MEFs were transfected with 1 µg vector 
using Fugene6 (F. Hoffmann-La Roche AG, Basel, Switzerland) for transient and stable 
transfection. Stable polyclonal transfectants were generated by selection with 0.5 mg/ml 
Geniticin/G418 (Invitrogen AG, Basel, Switzerland) over one month. RCC4 and hTERT RPE-
1 cells were transduced in the presence of polybrene (4 µg/ml) with viral supernatant 
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produced by 293Amphopack cells (Clontech-Takara Bio Europe, Otsu, Japan) transfected 
with VHL wild-type or mutants and selected with 4 µg/ml puromycin (Sigma Aldrich, St. 
Louis, MA, USA) over one month. Dimethyloxalyl glycine (DMOG) (Cayman chemical, Ann 
Arbor, MI, USA) treatment of generated MEF cell lines was performed over 24 hours at 
1 mM. DMOG experiments were independently repeated twice. 
 
Cloning of VHL mutants and HIF reporters 
VHL mutants were generated using the one-step PCR mutagenesis kit (Agilent Technologies 
Inc., Santa Clara, CA, USA) and pcDNA3.1-VHL including a hemagglutinin (HA) as template. 
The HIF reporter construct pcDNA3.1-HIF1α-GFP (HIF1α Gene ID: 15251) was kindly 
provided by Stefanie Lehmann (Institute of Biomedical Engineering, ETH Zurich, 
Switzerland). pcDNA3.1-HIF2α-GFP (HIF2α Gene ID: 2034) was obtained by PCR 
amplification of pcDNA3.1-HIF2α and cloned into SacII and NotI restriction sites of the 
pcDNA3.1-GFP vector. All constructs were sequence verified. 
 
pVHL stability assay in vitro 
RCC4 and hTERT RPE-1 cells stably expressing the control vector, wild-type VHL or VHL 
mutants were grown to 80-90% confluency in a 6-well format and then treated with 40 µg/ml 
cycloheximide (Invitrogen) for different timepoints (0h, 1.5h, 3h, 6h). Zero hours was taken 
as reference input for the western blot analysis. After incubation, cells were harvested, 
processed and analysed by Western Blot. Cycloheximide experiments were performed once 
for RCC4 wt, RCC4 Ser68Thr, and RCC4 Leu101Pro. Experiments for hTERT RPE-1 VHL 
wt were performed 3 times independently and once for hTERT RPE-1 Ser68Thr and hTERT 
RPE-1 Leu101Pro. 
 
Western Blot 
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Cells were lysed in RIPA buffer supplemented with protease inhibitors (F. Hoffmann-La 
Roche AG) for 30 min on ice. The protein concentration was determined using the BCA 
Protein Assay Kit (Thermo Fisher Scientific Inc., Waltham, IL, USA). Equal amounts of 
protein were loaded on a 4-12% gradient Bis-Tris gel (Invitrogen) and transferred onto a 
nitrocellulose membrane (Whatman, Dassel, Germany). Membranes were blocked for 1h in 
5% milk powder and then incubated with mouse anti-HA (1:1000 dilution; Invitrogen), rabbit 
anti-human VHL CT (1:1000 dilution; kindly provided by Wilhelm Krek), or mouse anti-β-actin 
(1:1000 dilution; Chemicon, Temecula, CA, USA) overnight at 4°C. Subsequently, 
membranes were incubated with the appropriate secondary antibody for 1h at RT. Proteins 
were detected using the ECL kit (Thermo Fisher Scientific Inc.). 
 
FACS analysis 
Cells were transiently transfected with HIF reporters and harvested after 24 h with trypsin 
and washed in PBS for the FACS analysis. The cells were then resuspended in FACS buffer 
(PBS, 2% FCS) and dispersed through a filter into a FACS tube (BD Bioscience, Franklin 
Lakes, New Jersey, USA). Cells were kept on ice in the dark until analysis with the FACS 
Calibur (BD Bioscience). The flow rate was adjusted to 200-300 events per second and 
10’000 events were measured in total per sample. Data analysis was performed using 
FlowJo (Tree Star, Inc., Ashland, OR, USA). All experiments were conducted in triplicates 
with the exception of the DMOG treatment where one experiment was done in a single well 
transfection format and a second one in duplicate. The error bars in the figures are +/- SD. 
 
Statistics 
Contingency table analysis, Chi-square correlation tests, Kaplan-Meier curves, and log rank 
tests were calculated using SPSS/PASW 18.0.0. GraphPad Prism 5 was used for Spearman 
correlation tests and 1 way ANOVA with Bonferroni's Multiple Comparison tests. A p-value of 
< 0.05 was considered significant. 
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Results 
 
VHL mutations in sporadic ccRCC 
Sequence analysis of VHL in 256 ccRCC cases resulted in 75 (29%) wild-type and 181 
(71%) mutated tumors (Fig. 1). Six tumors had two mutations. There were 88 (47%) point 
mutations, including one silent mutation, 13 (7%) splice mutations and 86 (46%) 
deletions/insertions. Point mutations were further subdivided into 22 (25%) nonsense and 65 
(75%) missense mutations. The deletions/insertions were split into 74 (86%) frameshift and 
12 (14%) in frame mutations. All mutations are listed in supplementary table S1. 
The distributions of nuclear differentiation grade (Fuhrman), tumor stage (pT) and VHL 
mutation type are summarized in supplementary table S2. Survival analysis revealed no 
significant differences neither between wild-type and mutated VHL nor between the different 
mutation types (Fig. 1B). The same was true when the mutations and the mutation types 
were subgrouped according to their exon locations.  
The distribution and number of the identified mutations and mutation types within the three 
exons of VHL are shown in Fig. 2A-J. The number of VHL mutations was significantly 
increased in exon 1 compared to exon 2 and exon 3. The most frequent mutated amino 
acids (aa) were found at positions 65 (whole dataset and nonsense, respectively, Fig. 2A 
and B), 135 (frameshift, Fig. 2C), 78 (missense, Fig. 2D), and 76 (in frame, Fig. 2E). A 
clustering of mutations was detected from aa 65 - 77 (nonsense), 61 - 64 / 131 - 137 
(frameshift), 86 - 89 / 111 - 119 (missense), and 66 - 76 (in frame).  
 
In silico characterization of VHL missense mutations and protein structure 
In a first step, we characterized the VHL missense mutations identified in our set of sporadic 
ccRCC using the Swiss PDB viewer ‘Deep View v.4.0’. This program predicts whether the 
locations of missense mutations are pVHL surface- or core-related. With a threshold of 
accessibility of the aa of > 9% (defined as surface; (29)) we obtained the most surface 
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mutations in exon 3 (n = 14), whereas the majority of the missense mutations in exons 1 (n = 
25) and 2 (n = 16) were assigned to the core (Fig. 3A). Calculating the surface to core ratio 
in pVHL (aa 53-213) resulted in similar values for exon 1 (1.9) and 2 (1.7) but a higher value 
for exon 3 (5.6). This suggests an increased probability of having surface mutations in exon 
3. Due to the crystallographic structure of the pVHL complex (pdb code 1lm8), 21 of 23 
missense mutations located on the surface of pVHL could be assigned to interact with either 
HIF, elongin C, or elongin B (Supplementary Table S1, Fig. 3C, (18)). The remaining 2 
missense mutations were not located in the domain of any known interaction partner. By 
using the software Crescendo which predicts the most essential regions and aa for protein-
to-protein interactions, most of the missense mutations were also allocated to these 
conserved regions. Other binding partners (reviewed in (35)) listed in supplementary table 
S1 were found to be influenced by the surface missense mutations (Trp88Cys: aPKC, 
Tyr98Asn: aPKC/CollIV/CARD9/SP1/KIF3A; Tyr112Asp: 
aPKC/CollIV/CARD9/SP1/KIF3A/CCT; Thr124Ala: CCT/aPKC/TD-NEM; Gln132Pro: CCT, 
Leu158Val: p53, Lys159Asn: p53, Arg161Pro: p53, Arg161Gln: p53). 
To predict changes of the pVHL structure due to missense mutations we used the program 
“Site Directed Mutator” (SDM). The algorithm calculates the thermodynamic change (ddG) 
caused by a mutation and output values with |ddG| > 2 are defined as “disease-associated”. 
By calculating the ddG values for all missense mutations we found 48% predicting a 
significant impact on the protein structure (ddG > 2) and the remaining 52% having “neutral” 
mutations (ddG < 2). A significant increased number of missense mutations changing the 
structure of pVHL was detected in exon 1 followed by exon 2 and 3 (Fig. 3D). When we split 
surface- and core- related mutations according to their exon locations, we observed 
‘disease-associated’ mutations primarily in the core of exon 1 and 2 and on the surface of 
exon 3 (Fig. 3F). 
 
In vitro characterization of VHL missense mutations and protein stability 
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To verify the predictive power of SDM on the thermodynamic change and stability of pVHL, 
we selected 6 missense mutations of which 4 were assigned disease-associated by protein 
destabilization (Ser68Thr, Gly93Glu, Leu101Pro, Tyr112Asp), 1 was assigned disease-
associated by protein stabilization (Pro86His), and 1 was neutral (Ser68Thr). Four of these 
missense mutations (Ser68Thr, Gly93Glu, Leu101Pro, Tyr112Asp) were stably transduced 
into the RCC4 tumor cell line and 6 (Ser68Thr, Gly93Glu, Leu101Pro, Tyr112Asp, Pro86His, 
Trp117Arg) into the hTERT-immortalized retinal pigment epithelial cell line (hTERT RPE-1). 
As expected, transduction of the negative control mutation Leu63fsX67 showed no 
expression in RCC4 and hTERT RPE-1 cells (Fig. 4A and B). In both cell lines, a pVHL 
expression pattern was observed after transduction of wild-type pVHL and the neutral pVHL 
mutant Ser68Thr as previously described (36). In contrast, the pVHL mutants Gly93Glu, 
Trp117Arg, and Leu101Pro which had the highest destabilizing ddG values of 2.9, 4.3, and 
6.1, respectively, showed much lower expression levels with bands between 20 and 30 kDa 
and additional abundant degradation products below 20 kDa which were not detected with 
the pVHL wild-type and the mutation Ser68Thr. The lower expression of the bands in these 
pVHL mutants were not due to decreased mRNA expression as verified by quantitative RT-
PCR analysis (data not shown). The pVHL mutant Tyr112Asp (ddG = 2.6) was only 
minimally affected by the mutation underscored by the detection of a faint additional band 
below 20 kDa compared to pVHL wild-type. Interestingly, the pVHL mutant Pro86His (ddG = 
2.3) expressed in the hTERT RPE-1 cell line showed an increased band intensity of full-
length pVHL (30 kDa) compared to the additional bands between 20 and 30 kDa present in 
the wild-type protein which reflects the predicted stabilizing effect of the mutation by SDM. 
To further investigate the stability of mutant proteins, a cycloheximide assay was performed 
with two selected missense mutations. pVHL wild-type and pVHL mutant Ser68Thr exhibited 
similar band intensities after 1.5, 3, and 6h cycloheximide treatment whereas the pVHL 
mutant Leu101Pro was clearly less stable (Fig. 4C and D). The bands between 20 and 30 
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kDa as well as the degradation product at 15 kDa were significantly decreased in intensity 
already after 1.5 h in the cell line hTERT RPE-1. 
 
In vitro characterization of VHL missense mutations and protein function 
To address the question whether the prediction of the stability of pVHL mutants influences its 
functionality, we set up a screening platform based on mouse embryonic fibroblasts negative 
for VHL and p53 (MEFs -/-). First, we transiently transfected hTERT RPE-1 and MEFs -/- 
with an N-terminally HA-tagged VHL expressed from the pcDNA3.1 vector using Fugene6 
with a vector DNA ratio 3:1, 3:2, and 6:1. In both cell lines, the expression pattern looked 
very similar (Fig. 5A). Interestingly, the HA western blot exhibited only one major band at 
approximately 30 kDa compared to the staining with anti-VHL CT suggesting an N-terminal 
processing of the full length pVHL. Next, we tested a set of HA-VHL mutant constructs for 
transient expression in MEFs -/- (Fig. 5B). As expected, the VHL mutant Leu101Pro with the 
highest destabilising value (ddG=6.1) showed the lowest expression levels similar to those 
shown in Figure 4A and C. To further establish our screening platform, we stably transfected 
MEF -/- cells with VHL wild-type and selected three independent polyclonal pools (batches 
1-3) to determine the batch specific variations (Fig. 5C). After selection, the expression 
levels of pVHL were similar for batches 2 and 3 and slightly lower in batch 1. Subsequently 
we transiently transfected these batches with a HIFα-GFP expression vector and verified the 
expression by western blot (data not shown), fluorescent microscopy (data not shown), and 
by quantitative measurement of expression by flow cytometry (FC) (Fig. 5D). Compared to 
MEFs -/- that were stably transfected with a negative control vector, the three batches were 
able to decrease the GFP signal by 73%, 63%, and 75% respectively (Fig. 5E). To validate 
the system, we added DMOG to MEF -/- VHL wild-type cells after transfection with HIFα-
GFP and measured the change of the FL-1 channel in gate 1 by FC 24h after transfection 
(Fig. 5F). As a control pmaxGFP was transfected. After addition of DMOG the GFP signal 
increased in both the HIF1α-GFP and HIF2α-GFP transfected MEF -/- VHL wild-type cells 
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2.1-fold and 2.2 fold, respectively. DMOG treated and untreated MEF -/- VHL wild-type cells 
transfected with pmaxGFP showed no increased GFP signals. Next, we generated MEFs -/- 
stably expressing the same set of VHL mutants (Fig. 5G) as we used for the transient 
expression (Fig. 5B). In contrast to the transient transfection experiments (see Fig. 5B), the 
MEFs -/- expressing the pVHL mutant Leu101Pro showed similar expression levels as VHL 
wt. 
Using our screening method we established MEFs -/- expressing 29 VHL missense 
mutations, of which 14 have already been described and 15 are not yet registered in the 
UMD database (13). Additionally, we included 5 well characterized controls, i.e. pVHL wild-
type, Leu63fsX67, Tyr98His, Tyr112His, and Tyr112Asn. MEF -/- Leu63fsX67 was used as 
negative control and was set to 100% GFP signal for both the HIF1α-GFP and the HIF2α-
GFP transfection experiments (Fig 6A-B). pVHL wild-type was capable of reducing the signal 
down to 40%. A comparable reduction was obtained with the VHL missense mutation 
Ser68Thr. The thermodynamic change of pVHL caused by this mutation was neutral (ddG = 
0.44) and not destabilizing. In addition, cycloheximide assays demonstrated that the stability 
of this mutant was similar to that of the wild-type pVHL, thus confirming our in silico data.  
A good correlation was seen between our in silico and in vitro findings when investigating 
other missense mutations in our dataset. For example, the pVHL destabilizing missense 
mutation Leu101Pro (ddG = 6.1) showed a severe loss-of-function represented by a GFP 
signal of 101% for HIF1α and 95% for HIF2α. It is of note, that the MEF cell line stably 
expressing pVHL Leu101Pro showed similar expression levels in western blots as pVHL wt 
(see Fig. 5G). Missense mutations described in VHL disease, such as Asn78Ser (Type 1; 
102% for HIF1α and 86% for HIF2α), Tyr98His (Type 2A; 62% for HIF1α and 55% for 
HIF2α), Tyr98Asn (Type 2B; 77% for HIF1α and 74% for HIF2α), and Ser80Asn (Type 2C; 
40% for HIF1α and 46% for HIF2α) yielded expected results. 
As an additional validation we also analyzed the impact of VHL frameshift mutations 
on the ability to degrade the two HIFα isoforms. For each of the three exons we generated 
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two frameshift mutations which were identified in our ccRCC patient set. All frameshift 
mutations except Glu204fsX44, which is located at the very end of exon 3, failed to 
destabilize HIF1α and HIF2α (Fig. 6C-D). As expected the frameshift mutations in all 3 
exons affected pVHL ability to degrade both HIFα isoforms in the same way (Fig. 6E). 
Most of the missense mutations affected HIF1α and HIF2α degradation equally (r = 0.9208, 
p < 0.0001). Notably, three VHL missense mutations showed a selectivity for either HIF1α 
(Asp121Tyr and Val130Phe) or HIF2α (Asn78Ser) in the range of 10 to 20% (Fig. 6F). 
Twelve missense mutations identified in our sporadic ccRCC set are also known to be VHL 
disease-related. The analysis of their effects on HIFα destabilization revealed a classification 
system of VHL mutation types that is similar to that described for VHL disease. In sporadic 
ccRCC this resulted in missense mutation type 1: HIFα-GFP expression mean 94% (+11%), 
type 2A: 58% (+3%), type 2B: 83% (+19%), and type 2C: 64% (+24%). 
Finally, we correlated the data obtained from pVHL stability prediction and functionality. 
Spearman correlation coefficient for HIF1α and HIF2α were r = 0.5741, p = 0.0006 and r = 
0.5494, p = 0.0011, respectively. A cut-off of 58% of the GFP signal for HIF1α and 54% for 
HIF2α resulted in 13 disease-associated missense mutations with a ddG > 2 for each of the 
HIF isoforms (Figure 6A and B, boxes A). Eleven (34%) and 16 (50%) mutations were 
predicted to be “neutral” but were compromised in their ability to ubiquitinate HIF1α and 
HIF2α, respectively (Figure 7A and B, boxes B). Only 8 (25%) and 3 (9%) missense 
mutations were identified with similar functionality on HIF1α and HIF2α destabilization, 
respectively, as pVHL wild-type (Figure 7A and B, boxes C).  
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Discussion 
In this study, we analyzed VHL missense mutations in sporadic ccRCC by 
determining their impact on pVHL’s functionality and HIFα stability using in silico and in vitro 
assays. The frequencies of the different VHL mutation types as well as their distribution over 
the three exons were highly comparable to the results described in previous publications (2, 
37).  
Our in silico approach enabled us to locate missense mutations to the surface or the core of 
pVHL. Most missense mutations (41 of 64) were located in the core of pVHL. The remaining 
23 missense mutations were assigned to the surface of pVHL from which 21 were localized 
within the binding domains of either HIFα, elongin B or elongin C. Most missense mutations 
were located in the elongin C interphase. Interestingly, mutations in the HIFα and elongin B 
binding sites favoured the formation of ccRCC in VHL syndrome patients, whereas 
mutations in the elongin C interphase were predisposed to developing pheochromocytoma 
(18). Surface and core missense mutations were equally distributed in hereditary VHL 
syndrome patients, whereas in our sporadic tumors 64% of the missense mutations were 
assigned to the core and 36% to the surface. Notably, over two-thirds of the surface 
missense mutations analysed in hereditary RCC were located in the interphase of elongin C 
(18) which is in agreement with our findings in sporadic ccRCC. We detected an 
accumulation of mutations in exon 1 where the binding site of HIF is located. In contrast, 
most mutations of hereditary VHL syndrome patients with ccRCC, retinal angioma, central 
nervous system hemangioblastoma, and pheochromocytoma were located in exon 3. 
Therefore, loss of VHL/HIF interaction is more common in sporadic ccRCC compared to its 
hereditary form. 
To resolve the question whether a missense mutation represents a driver mutation, which 
generates a growth advantage and thus potentially contributes to tumor formation, Carter 
and co-workers established a computational method termed Cancer-specific High-
throughput Annotation of somatic mutations (CHASM) (38). This approach is a powerful tool 
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to analyze missense mutations in multiple genes especially when structures of their gene 
products are not available. Due to the fact that the crystal structure of the pVHL/elongin 
B/elongin C complex is known, we used an algorithm which calculates the structural change 
caused by a specific missense mutation in this complex. Assuming that loss of pVHL 
function increases HIF transcriptional activity leading to tumor formation and progression, we 
have considered defining mutations with high structural changes as driver mutations. By 
calculating the thermodynamic stability of pVHL we obtained 30 destabilizing driver 
(“disease-associated”) and 32 (excl. 1 silent mutation) passenger (“neutral”) mutations. Most 
of the driver missense mutations were located in exon 1 suggesting that the majority of 
pVHL missense mutations in exon 1 predispose to ccRCC by affecting whole protein stability 
rather than disrupting binding to interaction partners. Only 38% of missense mutations in 
exon 3 were predicted to destabilize the whole protein structure. However, previous 
publications reported that loss of elongin binding to pVHL also leads to instability and rapid 
degradation of the protein (39-41). As all passenger surface-specific missense mutations in 
exon 3 localized to either elongin C or B it cannot be excluded that at least some of these 
mutations exert compromising effects to the regulation of HIF. Interestingly, a recent 
publication showed that although the missense mutation Arg167Gln causes loss of pVHL - 
elongin interaction, the HIFα ubiquitination was still functional (22). The authors suggested 
the formation of a remnant protein E3 ligase complex which is still partially capable of 
regulating HIF. 
To analyse the impact of pVHL missense mutations on the thermodynamic stability and HIF 
regulation in more detail, we established an in vitro screening platform based on mouse 
embryonic fibroblasts (MEFs) negative for VHL and generated polyclonal stable cell lines 
expressing various VHL mutants. We used MEFs because higher transient transfection 
efficiencies are obtained in comparison to pVHL negative RCC4 or 786-O cell lines. We 
performed all experiments using polyclonal batches with similar levels of pVHL rather than 
individually picked clones to avoid any possible selection for a specific cellular background. 
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Our in vitro platforms verified the predicted thermodynamic changes of ddG > 2 for the 4 
selected mutations which resulted in both pVHL degradation and HIF stabilization. 
Additionally, the bioinformatic approach could also correctly predict the impact of different aa 
exchanges at the same position. For example, the missense mutation at aa Arg161Pro (ddG 
= -2.86) was completely impaired and could not degrade HIFα as expected due to structural 
loss of pVHL, whereas the passenger mutation Arg161Gln (ddG = -0.54) retained 56% 
functionality. 
In the majority of the cases in our study, pVHL mutations affected both HIFα isoforms 
equally. Only three missense mutations seem to selectively influence HIF1α and HIF2α 
stability. However, whether these relatively modest differences are sufficient to significantly 
influence the tumor behavior remains elusive. A similar result was reported with the mutation 
Arg167Gln. Hypoxia experiments with murine embryonic stem cells showed that this 
mutation apparently was able to regulate HIF1α comparable to the wild-type but not HIF2α 
(42). This finding was validated by picking several VHL-/- clones transfected with the 
indicated mutant. In contrast, human 786-O cells stably expressing the same VHL mutant 
were able to regulate HIF2α expression upon CoCl2 treatment (22). Similar results were 
obtained by Bangiyeva et al., who saw comparable HIF2α levels in Arg167Gln, Arg167Trp, 
and pVHL wild-type expressing RCC10 cells (21). A contrasting result was published by 
Clifford and co-workers who detected impaired HIF regulation of both HIF isoforms in RCC4 
cells expressing Arg167Gln (43). These different findings may be explained by polyclonal 
and single cell clone selection, varying levels of exogenous pVHL expression, or by a cell 
line-specific recruitment of a remnant protein E3 ligase complex. 
The majority of the identified pVHL missense mutations affected both HIFα isoforms. 
Therefore it is tempting to speculate that additional factors on the activity (44), translational 
(45), and stability level selectively influence the expression levels of the HIFα isoforms (7, 
10, 11, 46). One prominent class in the stability regulatory network are the oxygen-
dependent prolyl 4-hydroxylases (PHDs) (47). PHDs hydroxylate both HIFα isoforms at 
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normoxic levels and allow the E3 ubiquitin ligase complex to interact with its substrate. It was 
suggested that different PHDs influence the levels of HIF1α or HIF2α depending on the cell 
type, the tissue, and the degree of oxygenation (48-51) which is independent of the VHL 
mutation status. 
Our in silico tool was able to group VHL missense mutations. The used algorithm proved to 
be a good predictor of pVHL functionality in terms of thermodynamic stability changes. By 
combining the results from our in silico and in vitro analyses, we obtained three different 
groups of missense mutations which a) lead to a severe destabilization of pVHL; b) have no 
destabilizing effects on pVHL but affect the interaction with HIFα, elongin B, and elongin C; 
and c) have functionalities comparable to the wild-type protein. The first two groups 
represent driver mutations whereas the latter one consists of passenger mutations. It is to 
note that 11 and 16 of 32 missense mutations predicted in silico to be “neutral” were 
compromised in their ability to ubiquitinate HIF1α and HIF2α, respectively. The higher 
number of missense mutations leading to HIF2α stabilization suggests a more specific 
binding of pVHL and HIF2α. Taken together, these results imply a gradient effect of pVHL 
missense mutations on HIF regulation which may be caused by a combination of structural 
changes and alterations of the binding capability to interaction partners. Our systematic 
approach enabled us to group these VHL mutations according to their effects on HIF which 
may have important implications for tumor behavior or response to therapy. However, the 
translation of the HIF (de)stabilizing impact of a VHL missense mutation into clinical 
application needs further investigation. 
Survival analysis of VHL wild-type, VHL mutation types, and subgrouping of VHL missense 
mutations into predicted destabilizing and neutral missense mutations, showed no differing 
effects on patient outcome. Our findings are in line with those described in a previous study 
(2) in which the impact of VHL mutation types on patient survival was also investigated. 
Based on these results it is tempting to speculate that the analysis of VHL mutations in 
ccRCC patients may serve as predictive rather than as prognostic tool. 
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In summary, the DNA sequence analysis of VHL in sporadic ccRCC identified known and not 
yet described VHL mutations. In addition, our in silico and in vitro analyses enabled us to 
classify VHL missense mutations into three different functional subgroups. The knowledge of 
the impact of a VHL missense mutation on pVHL and HIF stability helps to distinguish 
between driver and passenger mutations. In this scenario, assessment of the pVHL 
inactivation status may be useful in predicting response to HIF-targeted drugs. 
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Figure legends 
 
Figure 1. Sequence analysis of VHL in sporadic ccRCC. A, DNA was isolated from formalin 
fixed tissue and the VHL ORF subsequently sequenced which resulted in wild-type VHL and 
VHL with various types of mutations. B, Cumulative survival in ccRCC patients with different 
types of VHL mutations. 
 
Figure 2. Analysis of the VHL mutations. A - E, Mutation spectrum and frequency of all, 
nonsense, frameshift, missense, and in frame mutations found in VHL in sporadic ccRCC. 
Dotted lines represent exon boundaries. F - J, Percentage of mutations found after splitting 
pVHL into its exons 1 - 3 (* p < 0.05, ** p < 0.01, *** p < 0.001). Dotted lines represent VHL 
exon boundaries. 
 
Figure 3. Analysis of VHL missense mutations. A - B, VHL missense mutations were split 
according to their exon location in pVHL. Their position was further categorized into surface 
or core amino acids. C, surface missense mutations were categorized to their location in a 
specific binding partner domain (EloB = Elongin B, EloC = ElonginC = C, HIF = Hypoxia 
Inducible Factor) and their conservation. D, missense mutations were split into exons and 
the exons further subdivided into the thermodynamic change caused by the mutation (ddG > 
2 = disease-associated). E - F, deep and surface missense mutations were split into exons 
and ddG. * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Figure 4. Stability of VHL mutants. A, RCC4 and B, hTERT RPE-1 cell lines stably 
expressing VHL wild-type, negative control (Leu63fs67X), and indicated mutants with 
different predicted protein stabilities by SDM (ddG > 2 = disease-associated). The upper 
panel shows staining with anti human VHL CT with 3 major bands representing intact pVHL, 
pVHL isoforms and degradation products. The lower panel shows the appearance of 
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additional degradation products (10 and 15 kDa) after staining with anti human VHL CT and 
longer exposer time. β-actin was used as loading control. C - D, cycloheximide treatment 
was performed with cell lines expressing VHL wild-type and VHL mutants Ser68Thr and 
Leu101Pro with a ddG of 0.4 and 6.1, respectively. Cells were collected at the indicated 
time-points. Anti-VHL CT staining showed the same protein pattern as described in A. An 
unspecific band was used as loading control. 
 
Figure 5. Setup of VHL functionality screening platform. A, hTERT RPE-1 and MEFs -/- 
were transiently transfected with an N-terminally HA-tagged VHL expressed from the 
pcDNA3.1 vector using Fugene6 with a vector DNA ratio 3:1, 3:2, and 6:1. B, Transient 
expression in MEFs -/- of selected mutants. C, Three polyclonal batches of MEF-/- stably 
expressing re-introduced VHL wild-type and one batch transfected with pcDNA vector were 
generated. D, Flow cytometric (FC) read-out of transient HIF1α-GFP expression in MEF-/- 
with VHL mutant Leu63fs67X (negative control) was gated first into a life-gate with 
FSC/SSC. Subsequent analysis of GFP positive fraction in the histogram resulted in Gate 1. 
E, Batches described in 2A were transfected with HIF1α-GFP and the GFP signal monitored 
after 24h. F, MEF-/- VHL wild-type cells were treated with or without DMOG after transient 
transfection of HIF1α-GFP, HIF2α-GFP, or pmaxGFP and % positive cells counted in Gate 1 
after 24h. G, MEF-/- cell lines stably expressing HA-tagged VHL wild-type, negative control 
(Leu63fs67X), and indicated mutants. 
 
Figure 6. Influence of pVHL mutants on the destabilization of HIFα isoforms. A, MEF VHL 
negative / p53 negative cell lines stably expressing HA-tagged pVHL with various missense 
mutations were transiently transfected with pcDNA3.1-HIF1α-GFP and GFP expression 
measured 24h later with flow cytometry (FC). The pVHL mutant Leu63fs67X (negative 
control) was set to 100% for each replica. Black bars represent missense mutations not 
registered in the UMD database. B, same as in panel A but transfection with pcDNA3.1-
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HIF2α fusion. C, same as in panel A but with HA-tagged pVHL with various frameshift 
mutations. D, same as in panel B but with HA-tagged pVHL with various frameshift 
mutations. For A-D, experiments were conducted in triplicates. Error bars are +/- SDM. E, 
correlation of HIF1α-GFP and HIF2α-GFP signal in MEF -/- expressing the VHL frameshift 
mutations presented in Figure 6C and 6D. F, correlation of HIF1α-GFP and HIF2α-GFP 
signals in MEFs -/- expressing the VHL missense mutations presented in Fig 6A and 6B. 
Open circles represent missense mutations registered in the UMD database as VHL disease 
causing. Bars represent the range in which the specific VHL disease type was detected. 
 
Figure 7. Correlation of VHL stability and functionality. HIF GFP isoform signals were 
correlated to the thermodynamic change of mutated VHL (ddG). GFP signals of disease 
associated VHL mutants with ddG > 2 are in box A. Box B represents VHL mutations not 
predicted to be “disease-associated” by instability but with decreased ability to degrade 
HIFα. Box C shows VHL mutations with a functionality similar to VHL wild-type. 
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